The monthly spectrum anticancer drugs with a monthly fee of 230,000 passed the form of the National Medical Insurance Bureau!CAR-T also passed too

Zhongxin Jingwei, September 7th (Wang Yuling) On the 6th, the State Medical Security Bureau announced the "List of Medicine of National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogs in 2022". Form review.

Zhongxin Jingwei noticed that in the list of drugs reviewed in form, the broad -spectrum targeting drug sulfinin cymbal and sulfininibic solution developed by Bayer Pharmaceuticals. Diagnose the full -verified detection method as a fusion gene with neurotic tyrosine receptor agonase (NTRK) and does not include known mutations in obtaining sexual resistance. Patients, as well as patients who have no satisfactory treatment or failed to treat.

Judging from the reason for choice, the National Medical Insurance Administration stated that Larotinib is the world's first accurate targeting NTRK gene fusion drugs that have been approved for listing and are not limited. The product can be listed on the product.

According to public information, Larotinib was first approved for listing in the United States on November 26, 2018. In April 2022, Larotinib Capsules were officially listed by the National Drug Administration of China. It is worth noting that, according to public information, the pricing of sulfiniic acid oral capsules in the United States is relatively high, which is 32,800 US dollars per month, and the current exchange rate is 228,900 yuan. RMB 27.463 million.

In addition to sulfinic acid Larotinib capsules, Zhongxin Jingwei noticed that Yin Ming Junuo's CAR-T product Reiko Lencean injection also ranked among the list. It is used to treat the recurrence or refractory large B -cell lymphoma of adult patients after systematic treatment.

Previously, the pricing of the injection solution of Rock Olun was also high. On December 29, 2021, the centralized procurement network of drugs and medical consumables in Liaoning Province announced and implemented the results of innovative drugs directly hanging the network procurement. The size is about 5ml, and it contains no less than 25*10^6CAR-T cells.

Regarding the significance of preliminary form review, the State Medical Insurance Administration explained that the preliminary form review was preliminary review of whether the application of drugs to be adjusted and the integrity of the drug information of the national medical insurance and drugs. Preliminary review of drug declaration materials can be conducted. On the one hand, the drugs that can be declared can ensure that the application conditions are met, and on the other hand, the integrity and standardization of the declaration materials can be reviewed.

Regarding the formal review of high -priced drugs, the State Medical Insurance Administration stated that this year, some expensive drugs have passed preliminary review, which only indicates that the drug meets the application conditions and has obtained qualifications to enter the next link. Whether this type of medicine can eventually enter the national medical insurance drug catalog also needs to be strictly evaluated in many ways to include economics. The exclusive drugs that pass the review must be negotiated and the non -exclusive drugs must be bidded. Essence (For more report clues, please contact Wang Yuling, the author of this article: [email protected]) (Zhongxin Jingwei APP)

(The views in the article are for reference only, do not constitute investment suggestions, have risks in investment, and need to be cautious to enter the market.)

Editor in charge: Luo Yan

Pay attention to the official WeChat public account of JWVIEW (JWVIEW) to get more elite financial information.

- END -